Biologicals in atopic disease in pregnancy: An EAACI position paper
Autor: | Adam Chaker, Zsolt Szépfalusi, Juan José Yepes-Nuñez, Onur Boyman, A. Vultaggio, Alexia Chatzipetrou, Oscar Palomares, Cezmi A. Akdis, Marek Jutel, Eva Untersmayr, Andrea Matucci, Mohammad Alsalamah, Alanna Marson, Sevim Bavbek, Paula Kauppi, Birgit Pfaller, Barbara Rogala, Antonios G.A. Kolios, Sarah Bendien, Susan Chan, Ioana Agache, Thomas Eiwegger, Carmen Li, Apostolos Bossios, George Du Toit |
---|---|
Přispěvatelé: | HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, Helsinki University Hospital Area, University of Helsinki, University of Zurich, Eiwegger, Thomas |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Allergy Omalizumab GUIDELINES Inflammatory bowel disease Biological Factors 0302 clinical medicine 10183 Swiss Institute of Allergy and Asthma Research Multicenter Studies as Topic Immunology and Allergy atopic dermatitis 10177 Dermatology Clinic Atopic dermatitis CROHNS-DISEASE 3. Good health biologicals 2723 Immunology and Allergy Female Rituximab pregnancy medicine.drug medicine.medical_specialty 1ST TRIMESTER Immunology 610 Medicine & health OMALIZUMAB USE Dermatitis Atopic 03 medical and health sciences MANAGEMENT medicine Humans RITUXIMAB REGULATORY T-CELLS Intensive care medicine Asthma Biological Products 2403 Immunology Pregnancy business.industry Infant Newborn asthma medicine.disease body regions 030104 developmental biology 030228 respiratory system 3121 General medicine internal medicine and other clinical medicine 10033 Clinic for Immunology MODIFYING ANTIRHEUMATIC DRUGS Position paper business INFLAMMATORY-BOWEL-DISEASE |
Zdroj: | Allergy. 76:71-89 |
ISSN: | 1398-9995 0105-4538 |
Popis: | Biologicals have transformed the management of severe disease phenotypes in asthma, atopic dermatitis, and chronic spontaneous urticaria. As a result, the number of approved biologicals for the treatment of atopic diseases is continuously increasing. Although atopic diseases are among the most common diseases in the reproductive age, investigations, and information on half-life, pharmacokinetics defining the neonatal Fc receptors (FcRn) and most important safety of biologicals in pregnancy are lacking. Given the complex sequence of immunological events that regulate conception, fetal development, and the intrauterine and postnatal maturation of the immune system, this information is of utmost importance. We conducted a systematic review on biologicals in pregnancy for indications of atopic diseases. Evidence in this field is scare and mainly reserved to reports on the usage of omalizumab. This lack of evidence demands the establishment of a multidisciplinary approach for the management of pregnant women who receive biologicals and multicenter registries for long-term follow-up, drug trial designs suitable for women in the reproductive age, and better experimental models that represent the human situation. Due to the very long half-life of biologicals, pre-conception counseling, and health care provider education is crucial to offer the best care for mother and fetus. This position paper integrates available data on safety of biologicals during pregnancy in atopic diseases via a systematic review with a detailed review on immunological considerations how inhibition of different pathways may impact pregnancy. |
Databáze: | OpenAIRE |
Externí odkaz: |